Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06553053

Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial

The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shanghai Research Institute of Acupuncture and Meridian

Shanghai, China

Location status: Recruiting

Location contact

Bao Chunhui, MD, PhD

CONTACT

[email protected]

+862164395973

About this study

Acupuncture has been proven to be an effective and safe treatment for CD. In this trial, based on previous studies, which mainly treated CD from the perspective of spleen and stomach tonification, we explored the therapeutic effect of acupuncture in treating CD from the perspective of tonifying the Shaoyang pivot mechanism to enhance the therapeutic effect.Brain-gut axis dysfunction is one of the important pathogenic mechanisms of CD. This trial attempted to explore the therapeutic targets and efficacy mechanisms of acupuncture to enhance CD by analysing brain-gut axis multi-pathway indicators.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with clinical diagnosis consistent with CD;
  • aged 16-75;
  • patients in remission (CDAI < 150 and CRP < 5mg/l, or Faecal calprotectin < 50μg/g, or no ulcer under endoscopy);
  • patients with frequent disease recurrences (≥2) in the past years;
  • patients were not taking medication or were only taking one or more of the following drugs: [mesalazine (≤4g/d), prednisone (≤15mg/d), azathioprine (≤1mg/kg/d)] and prednisone and mesalazine were used for at least 1 month, while azathioprine was used for at least 3 months; or those who had poor response or loss of response to biological preparations (anti-TNF-α, IL-12p40, α4β7);
  • those who have never experienced acupuncture;
  • patients signing informed consent.

Exclusion criteria

  • patients who are recently pregnant or in pregnancy or lactation;
  • patients with serious organic diseases;
  • patients diagnosed as psychosis;
  • patients who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;
  • severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;
  • there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;
  • patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;
  • there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.

Treatment and study plan

"Harmonizing Shaoyang, nourishing spleen and kidney with warmth" Acupuncture Group

Other

Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV12 and bilateral ST36 and GB41 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, GB41, SP4, KI3, LI11, SJ4 and GB26 were selected for acupuncture and CV4 and bilateral SP6 and GB34 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.

"Nourishing spleen and kidney with warmth" Acupuncture Group

Other

Patients receiving acupuncture and mild moxibustion, whom were treated 2 times per week for 12 weeks and followed up for 40 weeks. The first group of acupoints is that CV4 and Bilateral ST37, SP6, SP4, KI3 and LI11 were selected for acupuncture and CV12 and bilateral ST36 were selected for moxibustion. The second group of acupoints is that CV12 and Bilateral ST36, SP4, KI3 and LI11 were selected for acupuncture and CV4 and bilateral SP6 were selected for moxibustion. These two groups are alternate. After deqi sensation was even reinforcing and reducing. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion. During each treatment, acupuncture and mild moxibustion are performed simultaneously, both lasting for 30 minutes.

Primary outcomes

  1. The proportion of recurrences

    Time frame: Week 52

    Defined as CDAI > 150 and increase ≥ 70 points, or emergency, hospitalization and surgical events due to worsening of CD conditions, or need to adjust drug to control disease condition.

Secondary outcomes

  1. Number of recurrences

    Time frame: Week 52

    Total number of recurrences. The median number will be counted for both groups.

  2. Time of recurrences

    Time frame: Week 52

    Time to first recurrence will be counted for both groups.

  3. Crohn's disease activity index (CDAI)score

    Time frame: Week 0, 6, 12, 24, 36 and 52

    The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.

  4. Patient Reported Outcome (PRO2)

    Time frame: Week 0, 6, 12, 24, 36 and 52

    The outcome is measured by level of abdominal pain (visual analogue scale, VAS) and number of diarrhoea in the past week.

  5. First laboratory tests

    Time frame: Week 0, 6, 12, 24, 36 and 52

    serum C-reactive protein (CRP)

  6. Second laboratory tests

    Time frame: Week 0, 6, 12, 24, 36 and 52

    erythrocyte sedimentation rate (ESR)

  7. Third laboratory tests

    Time frame: Week 0, 6, 12, 24, 36 and 52

    platelet count (PLT)

  8. Inflammatory bowel disease questionnaire (IBDQ)

    Time frame: Week 0, 12, 24, 36 and 52

    The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.

  9. Hospital anxiety and depression scale (HADS)

    Time frame: Week 0, 12, 24, 36 and 52

    The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.

  10. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)

    Time frame: Week 0, 12, 24, 36 and 52

    The mean change in FACIT-F from baseline. The higher the score, the worse the condition. The score range from 0 to 52.

  11. Colonoscopy or small bowel MR evaluation

    Time frame: Week 0 and 52

    measured by colonoscopy (SES-CD score) or small bowel MR (MaRIA score)

  12. Expectation of acupuncture treatment

    Time frame: Week 0

    measured by acupuncture treatment effectiveness expectation questionnaire

  13. Blind questionnaire

    Time frame: Week 6 and 12

    measured by patients guessing their grouping

Other outcomes

  1. Effects of acupuncture on brain network connectivity properties

    Time frame: Week 0 and 12

    Gray matter structure of the brain,functional connectivity and network properties of brain networks and local activity in brain regions were measured in an attempt to analyze the correlation between changes in these indicators after acupuncture intervention and the efficacy of acupuncture.

  2. Salivary cortisol

    Time frame: Week 0 and 12

    Salivary cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.

  3. α-Salivary Amylase

    Time frame: Week 0 and 12

    α-Salivary Amylase is measured by ELISA to analyze effect of acupuncture on HPA axis function.

  4. Serum cortisol

    Time frame: Week 0 and 12

    Serum cortisol is measured by ELISA to analyze effect of acupuncture on HPA axis function.

  5. Effect of acupuncture on autonomic nervous activity

    Time frame: Week 0 and 12

    The effect of acupuncture on autonomic function was recorded by DMS300-4AL.

  6. Effect of acupuncture on intestinal inflammation levels function

    Time frame: Week 0 and 12

    Intestinal inflammation levels are measured by C-reactive protein and plasma concentrations of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6.

  7. Effect of acupuncture on intestinal mucosal barrier function

    Time frame: Week 0 and 12

    Intestinal mucosal barrier function are measured by concentrations of lipopolysaccharide (LPS), Diamine oxidase (DAO) and D-lactate.

Study contacts

Contact information is provided by the study sponsor or research team.

Bao Chunhui, MD, PhD

CONTACT

[email protected]

+862164395973

Sponsors and collaborators

Lead sponsor

Shanghai Institute of Acupuncture, Moxibustion and Meridian

Other

Collaborators

  • Ruijin Hospital

Registry information

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Aug 14, 2024
Registry last updated
Apr 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.